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Abstract
Objective: Cross-sectional data show elevated levels of circulating cytokines in psychiatric
patients. The literature is divided concerning anti-inflammatory drugs’ ability to relieve
symptoms, questioning a causal link between inflammatory pathways and psychiatric condi-
tions. We hypothesised that the development of circulating cytokine levels is related to mental
distress, and that this relationship is affected by the use of anti-inflammatory drugs. Methods:
The study was a longitudinal assessment of 12-week inpatient treatment at Modum Bad
Psychiatric Center, Norway. Sera and self-reported Global Severity Index (GSI) scores, which
measure psychological distress, were collected at admission (T0), halfway (T1) and before dis-
charge (T2). Other variables known to distort the neuroimmune interplay were included. These
were age, gender, diagnosis of PTSD, antidepressants and anti-inflammatory drugs. A total of
128 patients (92 women and 36 men) were included, and 28 were using anti-inflammatory
medication. Multilevel modelling was used for data analysis. Results: Patients with higher levels
of IL-1RA and MCP-1 had higher GSI scores (p= 0.005 and p= 0.020). PTSD patients scored
higher on GSI than non-PTSD patients (p= 0.002). These relationships were mostly present
among those not using anti-inflammatory drugs (n= 99), with higher levels of IL-1RA and
MCP-1 being related to higher GSI score (p= 0.023 and 0.018, respectively). Again, PTSD
patients showed higher GSI levels than non-PTSD patients (p= 0.014). Conclusions:
Cytokine levels were associated with level of mental distress as measured by the GSI scores,
but this relationship was not present among those using anti-inflammatory drugs. We found
no association between cytokine levels and development of GSI score over time.
Significant outcomes
• Cytokines were related to level of mental distress in psychiatric inpatients.
• Cytokines were not related to the progression of mental distress in treatment over time.
• Anti-inflammatory drugs seemed to modify the relationship between cytokines and
mental distress.
Limitations
• Body mass index and smoking status were not assessed.
• The sample size was small and raises the question of type II error.
• Caution should be used in interpreting the results, as some patients had serum levels
under detectable limit.
• Patients were not fasting before blood collection.
Introduction
Several studies have found an association between cytokine levels and severity of mental distress
(Maes, 1995; Furtado &Katzman, 2015;Miller & Raison, 2016; Dalton et al., 2018).Meta-analyses
and systematic reviews of cross-sectional studies have shown that circulating pro-inflammatory
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cytokines, such as interleukin (IL)-1, IL-6, and tumour necrosis fac-
tor-alpha (TNF-α), are significantly elevated in depressed individ-
uals as well as in a broad spectre of other psychiatric diagnoses
compared to healthy controls (Dowlati et al., 2010; Passos et al.,
2015; Dalton et al., 2018). We have previously found both higher
levels and a distinct escalation during treatment of pro-inflamma-
tory and anti-inflammatory cytokines in patients with post-
traumatic stress disorder (PTSD), but not for other psychiatric
disorders (Toft et al., 2018). There is evidence of a causal pathway
from low-grade inflammation to depression, as raised inflammatory
markers have been found to precede depressive symptoms in
longitudinal studies (Valkanova et al., 2013). There is, however, also
evidence of an opposite direction, that is, mental distress preceding
an inflammatory response (Wang et al., 2017).
The notion that low-grade inflammation may lead to depres-
sion has been supported by a longitudinal study in the general
population reporting that elevated levels of IL-6 was associated
with psychological distress, and where low levels at the first
measurement and follow-up after 6 years were associated with
being symptom free (Virtanen et al., 2015). Other studies have
shown that patients with inflammatory diseases have greater risk
of depression (Maes, 2011; Miller & Raison, 2016), that repeated
exposure to systematic inflammation increased the risk of future
depressive symptoms among women (Bell et al., 2017), and
pro-inflammatory agents are known to induce depression as a side
effect (Schiepers et al., 2005; Köhler et al., 2016). This supports the
notion of causality. Furthermore, cytokines and psychiatric
symptoms in outpatients have been found to decline during treat-
ment (Dahl et al., 2016), and also to play a role in the progression
and severity of established depressive disorders in various popula-
tions (Young et al., 2014).
The growing understanding of inflammatory processes being
related to psychiatric disorders has led to clinical trials using
anti-inflammatory drugs in treatment of depressed patients. In
such studies, the use of non-steroidal anti-inflammatory drugs
(NSAIDs) has been associated with improved antidepressant treat-
ment response, suggesting an antidepressant effect of anti-inflam-
matory treatment (Köhler et al., 2014; Miller & Raison, 2016). It
has been speculated that some patients have low-grade inflamma-
tion as a trait and may benefit from anti-inflammatory drugs
(Morch et al., 2017). However, anti-inflammatory drugs alone have
shown a low to negligible effect on psychopathology (Eyre et al.,
2015), and may even contribute to more severe depression symp-
toms in patients treated with selective serotonin reuptake inhibi-
tors (SSRI), seemingly attenuating the central effect of the SSRI
treatment (Warner-Schmidt et al., 2011). Such results underline
the necessity that anti-inflammatory drugs are taken into consid-
eration when assessing cytokines and mental health.
Even if the effects of anti-inflammatory drugs on mental
distress seem to be ambiguous, it is probable that the use of such
drugs may influence the pathomechanism between inflammatory
processes andmental distress, as both NSAIDs (Müller et al., 2006)
and immuno-suppressants (Köhler et al., 2014) inhibit the produc-
tion of pro-inflammatory cytokines. The use of anti-viral drugs
may also interfere with cytokine levels (Canivet et al., 2015).
A 5-year follow-up study found higher levels of IL-1β, IL-1RA,
and TNF-α at the first measurement to be related to depressive
symptoms over time (van den Biggelaar et al., 2007), a finding sup-
ported by a literature review (Dantzer et al., 2008). There is also
evidence on cytokines being related to development of mental dis-
orders once it has already been established (Kim et al., 2019).
However, more research is needed as studies on the level of mental
distress seen in light of inflammatory biomarkers over time are still
scarce, with inconsistent findings (Eyre et al., 2015). In the present
study we hypothesised that there is an association between elevated
cytokine levels and mental distress in patients undergoing
treatment. Thus, we aimed to investigate the relationship between
cytokines levels and development of mental distress and the
potential moderating role of anti-inflammatory drugs.
Material and methods
Study participants and recruitment procedure
Patients were recruited from Modum Bad Psychiatric Center, a
specialised psychiatric centre in Norway, treating patients with
long-standing or treatment-resistant trauma, anxiety, eating and
depressive disorders. Patients with severe self-destructive behav-
iour or psychotic disorders were not eligible for admission. The
facility offered group and individual therapies in a 12-week
inpatient treatment programme. Therapy was paid by public
insurance, and patients in work were entitled to sick leave while
in treatment. Data were collected from March 2015 through
April 2016.
Patients were recruited from the Depression, the Eating, the
Anxiety, and the Trauma departments. The patients were admitted
in groups of eight at a time. They were given a 15 min presentation
during group therapy by the first author about the study during
one of the first days of their stay. Written information was handed
out, explaining the aim of the study and the procedures involved. A
consent form was also distributed to each potential participant.
Altogether 148 (59% of the total 249 patients approached) gave
their written consent. One individual withdrew her consent
2 weeks later. We excluded 19 patients from the data material
due to their having extreme cytokine levels above the 95th percen-
tile, indicating possible acute infections. These 95th percentile
limits were 436.6 pg/ml for IL-1RA and 216.3 pg/ml for MCP-1.
One patient had missing values in cytokine data due to failed veni-
puncture. Altogether the present study comprised data provided by
92 women (72%, mean age 39.04 years, SD 11.26) and 36men (28%,
mean age 49.06 years, SD9.36), giving a total of 128patients. The 102
patients who did not participate comprised 81 women (79%, mean
age 35.96, SD 11.77) and 21 men (21%, mean age 44.52, SD 8.58).
The material comprised venous blood samples and psychometric
data. The blood samples andHopkins SymptomChecklist 90 Revised
(HSCL-90R)questionnaireswere submittedwithin1 weekafter enter-
ing treatment (T0), at halfway (T1), and a few days before discharge
(T2). The study was approved by the Norwegian Regional Ethics
Committee prior to data collection (reference number 2014/2189).
Methods for clinical data
All patients were interviewed by trained psychologists or psychia-
trists using the MINI clinical interview (Sheehan et al., 1998). The
MINI interview gives diagnoses within the 10th revision of the
International Classification of Diseases and Related Health
Problems (ICD-10). The staff used a combination of psychometric
questionnaires and clinical judgement taken into consideration
when disorders were assessed. All disorders were in the spectrum
of depression, anxiety, and eating disorders. Fifty-four patients had
only one disorder, and 59 had two or more disorders. Thirty-two
patients had PTSD as primary diagnosis, some with one or even
two additional disorders. Fifteen patients had no registered
diagnosis due to missing data. An overview of diagnoses and
frequencies of the diagnoses are included in Supplementary
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Table S1. Patients completed the self-reporting questionnaire
HSCL-90R either on a computer or on a digital tablet. The
HSCL-90R is a 90-item questionnaire measuring levels of psycho-
logical distress during the past 7 days, each item ranging from 0 to
4, giving a mean score of all responses as the Global Severity
Index (GSI) (Derogatis et al., 1973). The questionnaire assesses
symptoms of somatisation, obsession and compulsion, depression,
anxiety, and hostility. The HSCL-90R has been shown to provide a
psychometrically valid evaluation of psychiatric patients regarding
the severity of depression, specific anxiety, and interpersonal sen-
sitivity (Bech et al., 2014). A cut-off for caseness was set to a GSI
score at 0.85 (Pedersen & Karterud, 2004). In comparison, a
previous study has found the GSI to be 0.49 in healthy controls
(Rytila-Manninen et al., 2016). The GSI is an overall scale taking
various symptoms into account, thus tapping into symptoms
common to a heterogeneous psychiatric patient sample (Rytila-
Manninen et al., 2016). At T0, all patients successfully submitted
their GSI scores, but at T1, data were missing on 6 patients and
at T2, on 13 patients. We also explored three subscales of the
HSCL-90R. These were the scales for somatisation, anxiety, and
depression. The pattern of missing values was the same as in
the GSI.
Anti-inflammatory drugs were NSAIDS, anti-viral drugs, and
immuno-suppressants. We do not know the exact indications
for which these drugs were given. The dichotomous anti-
inflammatory drugs variable was used to stratify the patients in
two groups. An overview of the anti-inflammatory drugs is
included in Supplementary Table S2. Patients were recorded as
users of these drugs if they had used such drugs at three occasions
or more during the treatment period. The drugs categorised as
anti-depressants were SSRIs, norepinephrine-dopamine reuptake
inhibitors (NDRI), tricyclic anti-depressives (TCAs), and serotonin-
norepinephrine reuptake inhibitors (SNRIs). The drugs in use were
recorded by looking into each patient’s medical charts.
Blood collection and serum preparation
The blood samples were drawn at T0, T1, and T2. They were col-
lected between 08:00 a.m. and 09:00 a.m., except for 16 patients
from the depression ward, who had their blood drawn between
12:00 am and 03:00 pm. Patients were not fasting and sat in an
upright position when blood was collected. Vacuette 8 ml serum
containers were used for blood collection. These were turned
upside-down 8–10 times immediately after the blood was collected,
and allowed to clot for 30–60 min. The samples were then spun at
1917 g for 10 min at room temperature. Separated serum samples
were immediately put to freeze at −80°C until assay.
Cytokine and chemokine measurements
We analysed seven cytokines and one chemokine based on the
available literature on the neuroimmune correlates of psychiatric
disorders: IL-1β, IL-1RA, IL-6, IL-10, IL-17A, IFN-y, MCP-1,
and TNF-α. Serum samples were thawed on ice, vortexed, and then
spun down a tube with 250 μl serum at 14 000 × g for 10 min at
4°C, before dilution (1 : 5) and further processing. The serum levels
were measured in picograms per millilitre (pg/ml). The cytokine
measurements were performed using Bio-Plex xMAP technology
(Bio-Rad, Austin, TX, USA) with a Luminex IS 100 instrument
(Bio-Rad, Hercules, CA, USA), powered using Bio-Plex Manager
(version 6.0.1) software. Multiplex bead–based technologies such
as Luminex allow detection and quantification of multiple cyto-
kines with good efficiency, speed, and dynamic range at reasonable
cost. The assay was performed according to the manufacturer’s
instructions, but an additional standard point was included. To
achieve a more reliable result, individual sets of samples from
patients were run in the same assay, all samples were assayed in
duplicate, and a magnetic plate washer was used during assay
set-up. The StatLIA software package (ver. 3.2; Brendan
Scientific, Carlsbad, CA, USA) incorporates a weighted, five-
parameter logistic curve-fitting method and was used to calculate
sample cytokine concentrations. One longitudinal control from
each participant was used for multiple analyses on each plate to
define the intra-plate CVs; IL-1RA (3.0%) and MCP-1 (4.0%).
Longitudinal controls were also used in order to validate the
inter-assay (i.e., between plates) coefficient of variability (CV).
The CVs were 10.2% for IL-1RA and 6.7% for MCP-1. An
inter-assay per cent CV of 10–12% is common (and acceptable).
The mean inter-assay per cent CV for all sample plates was
8.5%. The limit of detection (LOD) was 3 pg/ml for IL-1RA and
0.76 pg/ml for MCP-1.
Choice of cytokines and imputation
We investigated cytokine IL-1RA and chemokine MCP-1 due to
their robustness and very high detectability, a finding in line with
other studies (Leemasawatdigul & Gappa-Fahlenkamp, 2011;
Holub et al., 2013). Also, these cytokines had fewer than 6% below
LOD. Cytokine levels below the LOD were replaced with the LOD
value. Taking all three blood sampling occasions into considera-
tion, 423 samples were collected. For IL-1RA, we imputed one
value (0.2%). For MCP-1, we imputed 25 values (5.9%). We
excluded six of the cytokines due to a rather high number
of values below LOD. There were 194 (45.9%) values below
LOD for IL-1β, 148 (35.0%) for TNF-α, 200 (47.3%) for IL-6,
226 (53.4%) for IL-10, 384 (90.8%) for IL-17, and 332 (78.5%)
for interferon-gamma (IFN-γ).
Statistical analyses
The Mann–Whitney U-test and Pearson’s chi square were used
when analysing demographic data. Non-normally distributed
cytokines were attempted normalised by log-transformation. The
cytokines were, however, also skewed following log-transformation,
and the non-transformed cytokine values were ultimately used.
Multilevel models were used to assess the repeated measurements
of cytokines andGSI (Rabe-Hesketh& Skrondal, 2016).Main effects
of cytokines and cytokines in interaction with time were analysed.
We stratified the patients on the use of anti-inflammatory drugs
to specifically explore the potential effect of using such drugs.
This resulted in two groups (n= 28 for users and n= 99 for
non-users of such drugs). Power analysis was conducted with the
software G*Power, release 3.1.9.4, to assess the achieved statistical
power with the given sample size. With a standardised mean
difference of d = −0.54 (Köhler et al., 2014), the power was found
to be 0.71, giving a 29% chance of not finding an effect even if
present. Further, we specifically assessed the relationship between
PTSD and GSI since we have previously found the PTSD patients
to differ from patients without PTSD (Toft et al., 2018). We also
assessed the relationship between anti-depressants and GSI in
the aforementioned strata in order to distinguish potential effects
of different drugs. IL-1RA and MCP-1 were analyzed separately,
thus constituting trivariate multilevel analyses with time as
predictor variable, the cytokine as explanatory variable, and GSI
as dependent variable. The material comprised three measure-
ments of each patient, giving a structure of GSI score nested
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within patients. We disentangled the between- and within-subjects
effects from the total effects. The within-subjects effects represent
the expected change in GSI on average for a patient over the
12 weeks of treatment. The between-subjects effects indicate that,
on average, higher cytokine levels increase the GSI by the given
coefficient (Curran & Bauer, 2011). The process of disentangling
the within- and between-subjects effects involved group-mean
centering of the cytokine variables. The multilevel modelling
was performed in a stepwise approach with fixed effects of cyto-
kines and time, with subject ID as random intercept. A random
slope of time was added to allow the slopes to vary across time.
A likelihood ratio test was performed to assess model fit. The best
model fit was chosen based on the −2 Log Likelihood and Bayes
Information Criterion (BIC), and formally confirmed using likeli-
hood ratio test. A model with fixed effects and random intercept
gave a better fit than a model which included random slope (like-
lihood ratio test χ2(2)= 1.93, p= 0.381). The predicted fixed and
random effects of time on GSI are shown in Supplementary
Table S3. The assumption of linearity in the dependent GSI vari-
able across time was visually inspected with spaghetti plot and con-
sidered met. The assumption of homoscedastic residuals was
assessed with a likelihood ratio test (χ2(2) = 1.01, p= 0.603).
The non-significant test confirmed that the assumption of homo-
scedastic residuals was met. Normality of residual distribution was
assessed with QQ-plot and a histogram with a Gauss curve which
showed normally distributed residuals and a nearly perfect normal
curve. Restricted maximum likelihood (REML) was used in all
multilevel model estimations due to small sample size, and maxi-
mum likelihood (ML) was used for model comparison. Those who
did not submit all three GSI scores were defined as missing com-
pletely at random (MCAR), which indicated no specific pattern of
missing data. Consequently, there was no increased variability
which could have biased the regression coefficients. MCAR was
confirmed by Little’s MCAR test (Little, 1988) with χ2= 0.576
(p= 0.902). All tests were two-sided, and p-values below 0.05 were
considered statistically significant. No correction for multiple
hypothesis testing was implemented as we considered the study
to be exploratory. The HSCL-90R subscales anxiety, somatisation,
and depression were analysed, but did not provide different results
(included in Supplementary Table S4). Also, we explored all longi-
tudinal analyses with adjustment for age and sex, but this did not
significantly change any results (adjusted analyses are shown in
Supplementary Table S5). Therefore, we chose to present unadjusted
results. The statistical package STATA (StataCorp. 2015. Stata
Statistical Software: Release 15. College Station, TX: StataCorp
LP) was used for all statistical analyses.
Results
Table 1 shows demographic variables, cytokine levels, use of anti-
depressive medications, and PTSD diagnosis in those not using
or using anti-inflammatory drugs. There were significantly higher
levels ofMCP-1 and IL-1RA in those using anti-inflammatory drugs
(p< 0.001 and p= 0.026, respectively). There were also significantly
more patients without PTSD and without anti-depressive drugs
who also were not using anti-inflammatory drugs (p< 0.001 and
p= 0.008, respectively).
Table 2A and B presents the multilevel models of levels and
changes in GSI over time. The table is divided in three, where
Table 2A presents the results of all patients (n= 128), Table 2B
users of anti-inflammatory medication (n= 28) and Table 2C
non-users (n= 100 in total, with 99 of these patients submitted
blood samples). In Table 2A, each variable was run as a separate
explanatory variable on GSI, first as main effect only and then
in interaction with time. There was a significant main effect of
IL-1RA (p= 0.005), MCP-1 (p= 0.020) and having PTSD disorder
Table 1. Clinical information of study participants across the treatment period categorised on the use of anti-
inflammatory drugs
Variable
Not using Using
p-valuen= 100 n= 28
Demography
Women n (%) 69 (54%) 23 (18%) 0.018*
Age Mean (SD) 41.89 (11.61) 41.71 (11.67) 0.787†
Cytokines‡
IL-1RA Mean (SD) 36.96 (50.86) 43.08 (46.56) 0.026
MCP-1 Mean (SD) 25.53 (29.46) 34.56 (24.35) < 0.001
Mental distress
GSI Mean (SD) 1.32 (0.67) 1.53 (0.76) 0.033
Medication
Anti-depressants (not using) n (%) 76 (59%) 15 (12%) < 0.001
Anti-depressants (using) n (%) 24 (19%) 13 (10%)
PTSD diagnosis
No PTSD n (%) 58 (51%) 13 (11.5%) 0.008
PTSD n (%) 29 (26%) 13 (11.5%)
GSI, Global Severity Index; IL-1RA, interleukin-1 receptor antagonist; MCP-1, monocyte chemoattractant protein-1; PTSD, post-
traumatic stress disorder.
*Pearson chi square was used for categorical variables.
†The Mann–Whitney U-test was used for continuous variables.
‡Cytokine levels in picograms per millilitre (pg/ml).
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(p= 0.002) on GSI. The only variable related to the slope of GSI
over time was age (p= 0.025), indicating that older patients
improve more in mental distress over time.
Table 2B shows the main effect and interaction with time on
GSI in those patients using anti-inflammatory drugs. We found no
associations in this stratum. In those not using anti-inflammatory
drugs (Table 2C), there were significant main effects of IL-1RA
(p= 0.023), MCP-1 (p= 0.018) and having PTSD disorder
(p= 0.014) on GSI. Together, Tables 2B and C show that among
those not using anti-inflammatory drugs, GSI levels were
significantly higher in the PTSD sample compared to non-PTSD
patients. This difference was not present in those using anti-
inflammatory drugs. Time interaction did not show any significant
results in either of the two strata.
Table 2A. Trivariate linear mixed effects models of characteristics and mean cytokine levels across treatment
on GSI for all patients
Variable n
Main effect on GSI
Sig.
Interaction with time on GSI
Sig.β (SE) β (SE)
Age 128 −0.005 (0.005) 0.323 <−0.001 (< 0.001) 0.025
Women 92 0.175 (0.121) 0.152 −0.001 (0.010) 0.878
IL-1RA 127 0.004 (0.001) 0.005 <0.001 (0.001) 0.680
MCP-1 127 0.005 (0.002) 0.020 <0.001 (0.002) 0.809
PTSD diagnosis 42 0.356 (0.112) 0.002 0.014 (0.011) 0.152
Anti-inflam.* 28 0.224 (0.132) 0.093 0.017 (0.011) 0.108
Anti-depressives 76 −0.001 (0.102) 0.991 −0.004 (0.010) 0.676
GSI, Global Severity Index; β (SE), regression coefficient (standard error); IL-1RA, interleukin-1 receptor antagonist; MCP-1,
monocyte chemoattractant protein-1; PTSD, post-traumatic stress disorder.
Bold values represent significance value at p= 0.01, p= 0.05 and p= 0.01.
*Anti-inflammatory drugs. All regression models run with time as predictor variable.
Table 2B. Trivariate linear mixed effects models of characteristics and mean cytokine levels across treatment
on GSI for patients using anti-inflammatory drugs
Variable n
Main effect on GSI
Sig.
Interaction with time on GSI
Sig.β (SE) β (SE)
Age 28 −0.021 (0.011) 0.061 −0.002 (0.001) 0.092
Women 23 −0.031 (0.348) 0.930 0.011 (0.025) 0.659
IL-1RA 28 0.004 (0.003) 0.186 <−0.001 (< 0.001) 0.885
MCP-1 28 0.001 (0.006) 0.892 <−0.001 (< 0.001) 0.702
PTSD diagnosis 16 0.432 (0.273) 0.127 0.038 (0.021) 0.077
Anti-depressives 13 0.044 (0.204) 0.831 −0.020 (0.021) 0.359
GSI, Global Severity Index; β (SE), regression coefficient (standard error); IL-1RA, interleukin-1 receptor antagonist; MCP-1,
monocyte chemoattractant protein-1; PTSD, post-traumatic stress disorder.
All regression models run with time as predictor variable.
Table 2C. Trivariate linear mixed effects models of characteristics and mean cytokine levels across treatment
on GSI for patients not using anti-inflammatory drugs
Variable n
Main effect on GSI
Sig.
Interaction with time on GSI
Sig.β (SE) β (SE)
Age 100 <−0.001 (0.005) 0.992 <−0.001 (< 0.001) 0.101
Women 48 0.189 (0.128) 0.142 −0.006 (0.010) 0.577
IL-1RA 99 0.004 (0.002) 0.023 <0.001 (0.001) 0.623
MCP-1 99 0.006 (0.002) 0.018 <0.001 (0.002) 0.849
PTSD diagnosis 26 0.306 (0.122) 0.014 0.005 (0.011) 0.669
Anti-depressives 24 −0.032 (0.005) 0.787 −0.004 (0.012) 0.760
GSI, Global Severity Index; β (SE), regression coefficient (standard error); IL-1RA, interleukin-1 receptor antagonist; MCP-1,
monocyte chemoattractant protein-1; PTSD, post-traumatic stress disorder. IL-1RA, p= 0.023.
Bold values represent significance value at p= 0.05.
All regression models run with time as predictor variable.
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Fig. 1 shows the intercept and slope of GSI over time in the
patients according to their use of anti-inflammatory drugs.
There was a tendency that patients who used anti-inflammatory
drugs had higher level of GSI, also reflected in Table 2A
(p= 0.093). The slope of GSI in those who did not use anti-
inflammatory drugs was significantly different from zero
(β=−0.03, SE= 0.005, p< 0.001), indicating that there was a
reduction in symptoms over time. The slope of GSI in the users
of anti-inflammatory drugs did not reach significance in decline
over time (β=−0.01, SE= 0.01, p= 0.149), and the difference
between the two groups was not significant, as shown in Table
2A (p= 0.108).
Fig. 2A and B shows the intercepts and slopes of GSI over time
for the patients who did not use anti-inflammatory drugs, as shown
in Table 2C. The three slopes categorise the patients by the mean
level ± 1 SD of IL-1RA and MCP-1 according to their correspond-
ing GSI level. The slopes of the GSI scores declined throughout
treatment for all patients, and these slopes were significantly differ-
ent from zero (p< 0.001).
Discussion
In patients undergoing psychiatric treatment, those with higher
levels of IL-1RA and MCP-1 had higher levels of mental distress.
There was a decreasing slope of GSI over time for the older
patients, indicating that older patients benefited more from treat-
ment. When stratifying according to the use of anti-inflammatory
drugs during treatment, we found associations between levels of
cytokines and GSI only among those not using anti-inflammatory
drugs. There seemed to be an interaction between the use of anti-
inflammatory drugs and cytokine levels with the level of mental
distress in psychiatric patients in treatment. We did not find a
relationship between cytokine levels and the development of GSI
scores over time. We still believe our finding underscores the need
for taking anti-inflammatory drugs into account in immune-
psychiatric investigations and in treatment effect evaluation.
The relationship between cytokine level and degree of mental
distress is in line with numerous studies on many different groups
of patients with psychiatric diagnosis (Maes et al., 1990; Smith,
1991; Dowlati et al., 2010). The chemokine MCP-1 induces
leukocyte infiltration in the CNS and is associated with neuronal
damage, which is why it has been studied for its role in depression
(Young et al., 2014). Our finding that MCP-1 was related to level of
mental distress is in accordance with a series of studies. A review of
studies on inflammatory processes in major depressive disorder
showed that the synthesis of MCP-1 is involved in both the
aetiology and progress of the disorder (Young et al., 2014). The
association between elevated MCP-1 and depression and anxiety
symptom severity has also been found by others (Vogelzangs et al.,
2016), but results are mixed, as serum MCP-1 has also been found
to be lowered in patients with MDD (Young et al., 2014). The
anti-inflammatory cytokine IL-1RA is also known to be elevated in
depression and anxiety patients. The reason for this has been sug-
gested to be due to an increased innate immune response, which
involves both pro- and anti-inflammatory cytokine and chemokine
production (Maes et al., 1997; Dahl et al., 2014).
We did not find that cytokine levels were related to the
progress of mental distress. This discrepancy may have different
explanations. An observation period of 12 weeks may not be suf-
ficient to pick up on changes over time. Furthermore, patients
enrolled at Modum Bad Psychiatric Center were patients with
severe mental disease, often for many years, possibly carrying
Fig. 1. Intercept and slopes in users and non-users of anti-inflammatory drugs
depicting the decline levels of GSI (95% CI) during the treatment period.
Interaction effect of anti-inflammatory drugs with time on GSI. The graph visual-
ises the trajectories of the GSI from the multilevel model found in Table 2A. GSI,
GSI, Global Severity Index.
Fig. 2. (A and B) Intercepts and slopes of GSI in non-users (n= 99) of inflammatory
drugs.
The declining trajectories of GSI are explained by the time variable (as shown
in Supplementary Table S5). The GSI is categorised according to level of the
inflammatory markers (mean level ± 1 SD). The graphs visualise the trajectories
of the GSI from the multilevel models in Table 2C. GSI, Global Severity Index.
IL-1RA, interleukin-1 receptor antagonist; MCP-1, monocyte chemoattractant
protein-1.
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high cytokine levels as a trait feature. Also, the variety of diagno-
ses may explain a wide spread in cytokine levels in our study pop-
ulation. It has been suggested that anti-inflammatory drugs may
play a role in outcome of PTSD by altering neuro-immune proc-
esses (Miller et al., 2018; Waheed et al., 2018) and thus contribute
to mental recovery. Among those not using anti-inflammatory
drugs, the PTSD patients had significantly higher GSI levels
than non-PTSD patients. This difference was attenuated in those
using anti-inflammatory drugs. This implies that the use of anti-
inflammatory drugs affects GSI levels across PTSD diagnosis and
suggests other researchers in the field should assess the use of
such drugs in future studies of PTSD patients.
The relationship between cytokine level andmental distress was
only present among those not using anti-inflammatory drugs. The
lack of a relationship between cytokines andmental distress among
those using anti-inflammatory drugs may be that both the reason
for using these drugs, often an inflammation, and the drugs
themselves may influence the level of cytokines much more than
mental distress. Furthermore, it has been suggested that anti-
inflammatory drugs could be used in the treatment of depression,
as it reduces inflammation (Young et al., 2014), thus reducing
depressive symptoms, especially for the depression patients who
are labelled as treatment-resistant due to treatment unresponsive-
ness (Kornstein & Schneider, 2001). The mechanism is believed to
be the inhibition of enzyme cyclooxygenase-1 (COX-1). COX-1 is a
major player in modulation of pro-inflammatory microglia activa-
tion, and aspirin in particular has been postulated as particularly
promising, but still experimental and hypothetical (Baune, 2017).
However, the effect of anti-inflammatory medications has been
found to exhibit efficacy in treatment-resistant depression patients
with high-sensitivity CRP (hs-CRP) concentrations greater than
5 mg/l, but not for treatment-resistant depression with smaller
hs-CRP concentrations (Raison et al., 2013). This suggests sub-
groups of depression patients respond differently to drugs
according to inflammatory level. Together with our finding on
different associations in PTSD patients according to stratification,
a screening of inflammatory markers in patients seeking treatment
could be warranted.
There are some limitations to mention. The patients were not
fasting when blood samples were drawn. Eating has been found to
be associated with increased MCP-1 (Dixit et al., 2011). Body mass
index (BMI) of the patients was not assessed in this study. Adipose
tissue produces pro-inflammatory cytokines, meaning that body
fat is a possible confounder (Calder et al., 2011). We did not assess
smoking status. Smokers have been found to have a higher basal
level of cytokines when compared to non-smokers (Belchamber
et al., 2014). Physical exercise might affect the levels of circulating
cytokines (Phillips & Fahimi, 2018). We did not record the level of
exercise before blood samples were drawn. Conditions causing sys-
temic inflammation, for instance hepatitis, could potentially bias
the cytokine levels. The blood samples were collected in the after-
noon for 16 patients. During clotting, monocytes may begin
releasing MCP-1. However, increase in the protein levels of
MCP has been found only after several hours (Campbell et al.,
2017). Also, future studies will benefit from more sensitive assay
techniques as well as inclusion of multiple cytokines of the pro-,
anti-, and regulatory classes. The reader should bear in mind that
the sample size is small and there is a risk of type 2 errors. The study
showed that the levels of cytokine IL-1RA, chemokine MCP-1 and
PTSD diagnosis were related to level of GSI. The use of anti-
inflammatory drugs appeared to have an immunomodulating
effect on this relationship.
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